We collect cookies for vital website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.


Item № 11600
CAS № 957054-30-7
Purity ≥98%
product image
                (CAS 957054-30-7)
     10 mg $119.00 0.00
     50 mg $298.00 0.00
     100 mg $476.00 0.00

Pricing updated 2019-07-18. Prices are subject to change without notice.

  • GNE-0941
  • Pictilisib
  • Pictrelisib

The phosphatidylinositol 3-kinase (PI3K) signaling pathway has central roles in cell growth, development, and survival.1,2 GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K, inhibiting p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM, respectively.3,4 It is much less effective against class II-IV isoforms of PI3K and against mTOR.3,5 GDC-0941 inhibits the growth of certain types of cancer cells and blocks signaling through PI3K to Akt, both in cells and in vivo.3,6

Recommended Products

Related Products
View Related Product Categories
Technical Information
Formal Name
CAS Number
  • GNE-0941
  • Pictilisib
  • Pictrelisib
Molecular Formula
Formula Weight
A crystalline solid
213, 260, 319 nm
InChI Code
InChI Key

Warning - this product is not for human or veterinary use.

Shipping & Storage
Room temperature in continental US; may vary elsewhere
≥ 2 years
Downloads & Resources
Product Downloads

Download Product Insert

Download Safety Data Sheet (SDS)

Download free InChI Key generation software

Additional Information

View the Cayman Structure Database for chemical structure definitions for many Cayman products

Get Batch-Specific Data and Documents by Batch Number

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.

References & Product Citations
Product Description References

1. Hennessy, B.T., Smith, D.L., Ram, P.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery Nature Reviews.Drug Discovery 4, 988-1004 (2005).

2. Hirsch, E., Ciraolo, E., Ghigo, A., et al. Taming the PI3K team to hold inflammation and cancer at bay Pharmacology & Therapeutics 118, 192-205 (2008).

3. Folkes, A.J., Ahmadi, K., Alderton, W.K., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Journal of Medicinal Chemistry 51(18), 5522-5532 (2008).

4. Berndt, A., Miller, S., Williams, O., et al. The p110δ structure: Mechanisms for selectivity and potency of new PI(3)K inhibitors Nature Chemical Biology 6(2), 117-124 (2010).

5. Sutherlin, D.P., Sampath, D., Berry, M., et al. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors Journal of Medicinal Chemistry 53(3), 1086-1097 (2010).

6. Raynaud, F.I., Eccles, S.A., Patel, S., et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Molecular Cancer Therapeutics 8(7), 1725-1738 (2009).

Technical Support
Contact Us
  • Toll Free Phone (USA and Canada Only): (888) 526-5351
  • Direct Phone: (734) 975-3888
Cayman Contract Services

We work with scientists to accelerate their research, drug discovery, and drug development needs through our expertise in the following areas:

Cayman Chemical

1180 East Ellsworth Road

Ann Arbor, Michigan 48108 USA

Toll Free: (800) 364-9897

(USA and Canada Only)

Fax: (734) 971-3640